Photo Courtesy: www.ceoworld.biz
Consequently, the company will no longer carry out early stage research in neglected tropical diseases like TB and malaria.
The closure of this site will impact Astrazeneca's 168 full-time employees, who work on pharmaceutical development and drug discovery research into the neglected tropical disease.
Mr Sudhir Nambiar, site head and vice president, pharmaceutical development, R&D, Astrazeneca, Bangalore, said, "We realize this is a difficult news for our research colleagues in Bangalore and our priority is to support them over the coming months. We have not taken this decision lightly. We acknowledge the excellent work carried out by our people in Bangalore. These changes reflect the company's strategic focus on investing in our core therapy areas and simplifying our R&D footprint."
Pharmaceutical development projects currently carried out at the site will either transfer to its Macclesfield site in the UK, or be carried out by external providers said the company's press release.
However, AstraZeneca will continue to provide expertise to help advance existing third-party neglected tropical diseases programmes for the benefit of patients.
Employees affected by the changes will start leaving the company at the end of April this year.